Antibiotice Ia (ATB) - Total Liabilities
Based on the latest financial reports, Antibiotice Ia (ATB) has total liabilities worth RON548.43 Million RON (≈ $125.93 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see Antibiotice Ia total assets.
Antibiotice Ia - Total Liabilities Trend (2020–2025)
This chart illustrates how Antibiotice Ia's total liabilities have evolved over time, based on quarterly financial data. See ATB working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Antibiotice Ia Competitors by Total Liabilities
The table below lists competitors of Antibiotice Ia ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Republic Digital Acquisition Company Class A Ordinary Shares
NASDAQ:RDAG
|
USA | $12.83 Million |
|
Huida Sanitary Ware Co Ltd
SHG:603385
|
China | CN¥1.10 Billion |
|
Chongqing New Dazheng Property Grp
SHE:002968
|
China | CN¥721.97 Million |
|
CapMan Oyj B
HE:CAPMAN
|
Finland | €155.63 Million |
|
HD Renewable Energy Co. Ltd.
TW:6873
|
Taiwan | NT$9.25 Billion |
|
Hynar Water Group Co. Ltd.
SHE:300961
|
China | CN¥1.89 Billion |
|
Sinopower Semiconductor
TWO:6435
|
Taiwan | NT$965.21 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Antibiotice Ia's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ATB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Antibiotice Ia's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Antibiotice Ia (2020–2025)
The table below shows the annual total liabilities of Antibiotice Ia from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | RON460.49 Million ≈ $105.73 Million |
+19.62% |
| 2024-09-30 | RON384.95 Million ≈ $88.39 Million |
+31.74% |
| 2023-09-30 | RON292.21 Million ≈ $67.10 Million |
+35.88% |
| 2022-09-30 | RON215.04 Million ≈ $49.38 Million |
-25.95% |
| 2021-09-30 | RON290.40 Million ≈ $66.68 Million |
+1.63% |
| 2020-09-30 | RON285.73 Million ≈ $65.61 Million |
-- |
About Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system prepar… Read more